Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Evofem to hold a pharmaceutical update conference call » 08:25
05/26/20
05/26
08:25
05/26/20
08:25
EVFM

Evofem

$4.98 /

+0.18 (+3.75%)

Conference call to…

Conference call to discuss the FDA approval of Phexxi will be held on May 26 at 8:30 am. Webcast Link

ShowHide Related Items >><<
EVFM Evofem
$4.98 /

+0.18 (+3.75%)

EVFM Evofem
$4.98 /

+0.18 (+3.75%)

04/16/20 Roth Capital
Roth believes Evofem 'underappreciated' ahead of Phexxi PDUFA date
12/18/19 Roth Capital
Evofem's Amphora getting closer to FDA approval, says Roth Capital
12/11/19 H.C. Wainwright
Evofem price target raised to $11 from $9 at H.C. Wainwright
10/16/19 Cantor Fitzgerald
Evofem assumed with an Overweight at Cantor Fitzgerald
EVFM Evofem
$4.98 /

+0.18 (+3.75%)

Conference/Events
Evofem to hold a pharmaceutical update conference call » 04:55
05/26/20
05/26
04:55
05/26/20
04:55
EVFM

Evofem

$4.98 /

+0.18 (+3.75%)

Conference call to…

Conference call to discuss the FDA approval of Phexxi will be held on May 26 at 8:30 am. Webcast Link

ShowHide Related Items >><<
EVFM Evofem
$4.98 /

+0.18 (+3.75%)

EVFM Evofem
$4.98 /

+0.18 (+3.75%)

04/16/20 Roth Capital
Roth believes Evofem 'underappreciated' ahead of Phexxi PDUFA date
12/18/19 Roth Capital
Evofem's Amphora getting closer to FDA approval, says Roth Capital
12/11/19 H.C. Wainwright
Evofem price target raised to $11 from $9 at H.C. Wainwright
10/16/19 Cantor Fitzgerald
Evofem assumed with an Overweight at Cantor Fitzgerald
EVFM Evofem
$4.98 /

+0.18 (+3.75%)

Friday
Conference/Events
Evofem to hold a pharmaceutical update conference call » 17:07
05/22/20
05/22
17:07
05/22/20
17:07
EVFM

Evofem

$4.98 /

+0.18 (+3.75%)

Conference call to…

Conference call to discuss the FDA approval of Phexxi will be held on May 26 at 8:30 am. Webcast Link

ShowHide Related Items >><<
EVFM Evofem
$4.98 /

+0.18 (+3.75%)

EVFM Evofem
$4.98 /

+0.18 (+3.75%)

04/16/20 Roth Capital
Roth believes Evofem 'underappreciated' ahead of Phexxi PDUFA date
12/18/19 Roth Capital
Evofem's Amphora getting closer to FDA approval, says Roth Capital
12/11/19 H.C. Wainwright
Evofem price target raised to $11 from $9 at H.C. Wainwright
10/16/19 Cantor Fitzgerald
Evofem assumed with an Overweight at Cantor Fitzgerald
EVFM Evofem
$4.98 /

+0.18 (+3.75%)

Hot Stocks
FDA approves Evofem's Phexxi gel for prevention of pregnancy » 16:07
05/22/20
05/22
16:07
05/22/20
16:07
EVFM

Evofem

$5.02 /

+0.22 (+4.58%)

Evofem announced that the…

Evofem announced that the FDA has approved Phexxi vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception. Phexxi is the first non-hormonal, on-demand, vaginal pH regulator contraceptive designed to maintain vaginal pH within the normal range of 3.5 to 4.5 - an acidic environment that is inhospitable to sperm. The company expects to launch Phexxi in early September alongside the Phexxi Concierge Experience, a comprehensive patient and healthcare provider telemedicine support system.

ShowHide Related Items >><<
EVFM Evofem
$5.02 /

+0.22 (+4.58%)

EVFM Evofem
$5.02 /

+0.22 (+4.58%)

04/16/20 Roth Capital
Roth believes Evofem 'underappreciated' ahead of Phexxi PDUFA date
12/18/19 Roth Capital
Evofem's Amphora getting closer to FDA approval, says Roth Capital
12/11/19 H.C. Wainwright
Evofem price target raised to $11 from $9 at H.C. Wainwright
10/16/19 Cantor Fitzgerald
Evofem assumed with an Overweight at Cantor Fitzgerald
EVFM Evofem
$5.02 /

+0.22 (+4.58%)

Hot Stocks
Evofem gets FDA approval for new dosage form of Phexxi » 11:57
05/22/20
05/22
11:57
05/22/20
11:57
EVFM

Evofem

$4.48 /

-0.32 (-6.67%)

Evofem's Phexxi is a…

Evofem's Phexxi is a combination of lactic acid, citric acid, and potassium bitartrate indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception, prescribing information posted to the FDA website indicates. Reference Link

ShowHide Related Items >><<
EVFM Evofem
$4.48 /

-0.32 (-6.67%)

EVFM Evofem
$4.48 /

-0.32 (-6.67%)

04/16/20 Roth Capital
Roth believes Evofem 'underappreciated' ahead of Phexxi PDUFA date
12/18/19 Roth Capital
Evofem's Amphora getting closer to FDA approval, says Roth Capital
12/11/19 H.C. Wainwright
Evofem price target raised to $11 from $9 at H.C. Wainwright
10/16/19 Cantor Fitzgerald
Evofem assumed with an Overweight at Cantor Fitzgerald
EVFM Evofem
$4.48 /

-0.32 (-6.67%)

Over a week ago
Conference/Events
Roth Capital pharmaceuticals analysts to hold analyst/industry conference call » 11:25
05/13/20
05/13
11:25
05/13/20
11:25
EVFM

Evofem

$4.97 /

-0.09 (-1.78%)

Pharmaceuticals Analysts,…

Pharmaceuticals Analysts, along with Dr. Jonathan Zenilman, discuss Evofem Biosciences' Amphora's potential for STI (sexually transmitted infections) on an Analyst/Industry conference call to be held on May 13 at 12 pm.

ShowHide Related Items >><<
EVFM Evofem
$4.97 /

-0.09 (-1.78%)

EVFM Evofem
$4.97 /

-0.09 (-1.78%)

04/16/20 Roth Capital
Roth believes Evofem 'underappreciated' ahead of Phexxi PDUFA date
12/18/19 Roth Capital
Evofem's Amphora getting closer to FDA approval, says Roth Capital
12/11/19 H.C. Wainwright
Evofem price target raised to $11 from $9 at H.C. Wainwright
10/16/19 Cantor Fitzgerald
Evofem assumed with an Overweight at Cantor Fitzgerald
EVFM Evofem
$4.97 /

-0.09 (-1.78%)

Conference/Events
Roth Capital pharmaceuticals analysts to hold analyst/industry conference call » 04:55
05/13/20
05/13
04:55
05/13/20
04:55
EVFM

Evofem

$5.06 /

-0.05 (-0.98%)

Pharmaceuticals Analysts,…

Pharmaceuticals Analysts, along with Dr. Jonathan Zenilman, discuss Evofem Biosciences' Amphora's potential for STI (sexually transmitted infections) on an Analyst/Industry conference call to be held on May 13 at 12 pm.

ShowHide Related Items >><<
EVFM Evofem
$5.06 /

-0.05 (-0.98%)

EVFM Evofem
$5.06 /

-0.05 (-0.98%)

04/16/20 Roth Capital
Roth believes Evofem 'underappreciated' ahead of Phexxi PDUFA date
12/18/19 Roth Capital
Evofem's Amphora getting closer to FDA approval, says Roth Capital
12/11/19 H.C. Wainwright
Evofem price target raised to $11 from $9 at H.C. Wainwright
10/16/19 Cantor Fitzgerald
Evofem assumed with an Overweight at Cantor Fitzgerald
EVFM Evofem
$5.06 /

-0.05 (-0.98%)

Earnings
Veritiv Evofem reports Q1 EPS (40c), consensus (32c) » 08:03
05/06/20
05/06
08:03
05/06/20
08:03
EVFM

Evofem

$5.10 /

-0.15 (-2.86%)

"We are now less…

"We are now less than three weeks away from the PDUFA date for Phexxi and the potential to deliver the first non-hormonal contraceptive innovation in decades. We are encouraged by our ongoing discussions with the FDA regarding the potential label for Phexxi and we look forward to sharing more details about our unique Phexxi TeleContraception platform and other launch initiatives on today's call," said CEO Saundra Pelletier. "Our recent strategic financing agreement for up to $25M, coupled with our disciplined approach to resource allocation, gives us the financial flexibility we need to ensure that Phexxi gets the launch it deserves. If approved, we plan to launch Phexxi in early September along with a robust offering of support services designed to facilitate access to Phexxi and establish Evofem as a leader in women's health."

ShowHide Related Items >><<
EVFM Evofem
$5.10 /

-0.15 (-2.86%)

04/16/20 Roth Capital
Roth believes Evofem 'underappreciated' ahead of Phexxi PDUFA date
12/18/19 Roth Capital
Evofem's Amphora getting closer to FDA approval, says Roth Capital
12/11/19 H.C. Wainwright
Evofem price target raised to $11 from $9 at H.C. Wainwright
10/16/19 Cantor Fitzgerald
Evofem assumed with an Overweight at Cantor Fitzgerald
Earnings
Veritiv Evofem reports Q1 EPS (40c), consensus (32c) » 08:02
05/06/20
05/06
08:02
05/06/20
08:02
EVFM

Evofem

$5.10 /

-0.15 (-2.86%)

"We are now less…

"We are now less than three weeks away from the PDUFA date for Phexxi and the potential to deliver the first non-hormonal contraceptive innovation in decades. We are encouraged by our ongoing discussions with the FDA regarding the potential label for Phexxi and we look forward to sharing more details about our unique Phexxi TeleContraception platform and other launch initiatives on today's call," said CEO Saundra Pelletier. "Our recent strategic financing agreement for up to $25M, coupled with our disciplined approach to resource allocation, gives us the financial flexibility we need to ensure that Phexxi gets the launch it deserves. If approved, we plan to launch Phexxi in early September along with a robust offering of support services designed to facilitate access to Phexxi and establish Evofem as a leader in women's health."

ShowHide Related Items >><<
EVFM Evofem
$5.10 /

-0.15 (-2.86%)

04/16/20 Roth Capital
Roth believes Evofem 'underappreciated' ahead of Phexxi PDUFA date
12/18/19 Roth Capital
Evofem's Amphora getting closer to FDA approval, says Roth Capital
12/11/19 H.C. Wainwright
Evofem price target raised to $11 from $9 at H.C. Wainwright
10/16/19 Cantor Fitzgerald
Evofem assumed with an Overweight at Cantor Fitzgerald
Conference/Events
Roth Capital pharmaceuticals analysts to hold analyst/industry conference call » 16:01
05/05/20
05/05
16:01
05/05/20
16:01
EVFM

Evofem

$5.08 /

-0.17 (-3.24%)

Pharmaceuticals Analysts,…

Pharmaceuticals Analysts, along with Dr. Jonathan Zenilman, discuss Evofem Biosciences' Amphora's potential for STI (sexually transmitted infections) on an Analyst/Industry conference call to be held on May 13 at 12 pm.

ShowHide Related Items >><<
EVFM Evofem
$5.08 /

-0.17 (-3.24%)

04/16/20 Roth Capital
Roth believes Evofem 'underappreciated' ahead of Phexxi PDUFA date
12/18/19 Roth Capital
Evofem's Amphora getting closer to FDA approval, says Roth Capital
12/11/19 H.C. Wainwright
Evofem price target raised to $11 from $9 at H.C. Wainwright
10/16/19 Cantor Fitzgerald
Evofem assumed with an Overweight at Cantor Fitzgerald

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.